Analyst Ratings for Ambrx Biopharma
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 8 analysts have published their opinion on Ambrx Biopharma (NASDAQ:AMAM) stock. The analysts have an average price target of $23.5 versus the current price of Ambrx Biopharma at $8.0, implying upside. This current average has increased by 34.29% from the previous average price target of $17.50.
October 23, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts predict a significant upside for Ambrx Biopharma, with an average price target of $23.5, which is significantly higher than the current price of $8.0.
The average price target set by analysts indicates a significant potential upside for Ambrx Biopharma. This is likely to attract investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100